New Genmab/Seagen drug will cost up to USD 120,000

Patients being treated for cervical cancer in the US will pay a considerable sum to be treated with Genmab and Seagen's newly approved drug Tivdak, which the two companies will market together in the country.
Photo: Lars Møller / Genmab / PR
Photo: Lars Møller / Genmab / PR
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY CATHERINE BRETT AND DANIEL PEDERSEN

This week's FDA approval of cervical cancer drug Tivdak is a historic one for Genmab. Although the company does have other approved drugs on the market – Darzalex, Kesimpta and Tepezza – this marks the first time that the company will market one of its own drugs.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading